CHA Vaccine Research Institute Logo

CHA Vaccine Research Institute

Develops vaccines and immunotherapies for infectious diseases and cancer using proprietary platforms.

261780 | KO

Overview

Corporate Details

ISIN(s):
KR7261780001
LEI:
Country:
South Korea
Address:
경기도 성남시 중원구 둔촌대로 560, 406,407호(상대원동, 벽산테크노피아), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CHA Vaccine Research Institute is a clinical-stage biotechnology company specializing in the development of therapeutic and prophylactic vaccines and immunotherapeutics. A member of the CHA Medical and Bio Group, the company focuses on preventing and treating infectious diseases and cancer. Its core pipeline includes a third-generation hepatitis B (HBV) vaccine, a therapeutic vaccine for chronic HBV, a recombinant zoster (shingles) vaccine, and an improved influenza vaccine. The company leverages proprietary immune adjuvant platform technologies, such as L-pampo, and its own messenger RNA (mRNA) delivery system to enhance vaccine efficacy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 103.5 KB
2025-08-25 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 7.1 KB
2025-08-25 00:00
Board/Management Information
대표이사변경
Korean 8.9 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.0 MB
2025-08-08 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 53.2 KB
2025-07-15 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2025-07-15 00:00
Pre-Annual General Meeting Information
주주총회소집결의 (임시주주총회)
Korean 8.0 KB
2025-07-08 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험결과) (재조합 대상포진 백신(CVI-VZV-001)의 제 1상 임상시험 결과보고서 수령)
Korean 29.2 KB
2025-06-25 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-06-20 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험결과) (만성B형간염 치료백신 CVI-HBV-002의 2b상 임상시험 결과보고서 수령)
Korean 13.8 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1007.7 KB
2025-04-18 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험결과) (재조합 대상포진 백신(CVI-VZV-001)의 제 1상 임상시험 Topline …
Korean 22.7 KB
2025-04-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 23.7 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.4 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 27.9 KB

Automate Your Workflow. Get a real-time feed of all CHA Vaccine Research Institute filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CHA Vaccine Research Institute

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CHA Vaccine Research Institute via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
Matinas BioPharma Holdings, Inc. Logo
Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.
United States of America
MTNB
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel
MTLF
Maze Therapeutics, Inc. Logo
Develops genetic precision medicines for common diseases, with a focus on chronic kidney disease.
United States of America
MAZE

Talk to a Data Expert

Have a question? We'll get back to you promptly.